What is the expected growth forecast for the Afoxolaner Chewable Tablets market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033, driven by increasing pet ownership.

What are the key drivers of the Afoxolaner Chewable Tablets market?

Key drivers include rising demand for flea and tick control products and growing awareness of pet health.

What are the major challenges facing the Afoxolaner Chewable Tablets market?

Challenges include intense competition, stringent regulatory requirements, and concerns over antibiotic resistance.

Which regions are leading the Afoxolaner Chewable Tablets market?

North America and Europe are the leading regions, accounting for over 60% of the global market share.

Who are the top companies in the Afoxolaner Chewable Tablets market?

Top companies include Zoetis, Merck, and Elanco, which offer a range of flea and tick control products.

What future opportunities exist in the Afoxolaner Chewable Tablets market?

Future opportunities include the development of new products with improved efficacy and safety profiles.

How is technology impacting the Afoxolaner Chewable Tablets market?

Technology is driving innovation in product development, manufacturing, and distribution, enhancing the future outlook.

What is the current regulatory landscape for the Afoxolaner Chewable Tablets market?

The regulatory landscape is complex, with stringent requirements for product approval, labeling, and advertising.

How will the Afoxolaner Chewable Tablets market evolve in the next 5 years?

The market will evolve through increased competition, emerging technologies, and shifting consumer preferences, influencing the market size.

Afoxolaner Chewable Tablets Market Potential & Strategic Outlook 2033

Afoxolaner Chewable Tablets by Application (Tick Infection in Dogs, Gastrointestinal Nematode Infection in Dogs, Other), by Types (Afoxolaner Chewable Tablets, Afoxolaner and Milbemycin Oxime Chewable Tablets), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 73

Forecast Period: 2026 - 2033

Market Size: $2.5 million

CAGR: 0.065%

Historical Range: 2020 - 2025

Dec 15, 2025Updated: Jun 8, 2026

Pages: 73

Forecast Period: 2026 - 2033

Market Size: $2.5 million

CAGR: 0.065%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Afoxolaner Chewable Tablets Market Overview

The Afoxolaner Chewable Tablets market refers to the global industry involving the production and distribution of chewable tablets containing afoxolaner, a parasiticide used to treat flea and tick infestations in dogs. As the Afoxolaner Chewable Tablets market size is anticipated to witness significant growth, driven by the increasing demand for effective flea and tick control solutions, the growth outlook and market forecast indicate a promising future for industry players. The industry expansion is expected to be fueled by factors such as the rising pet ownership, growing awareness about flea and tick-borne diseases, and advancements in parasiticide technology. According to recent reports, the current Afoxolaner Chewable Tablets market size is approximately $1.3 billion, with a growth forecast of 7.5% CAGR from 2026 to 2033.

Loading chart…

Key forces shaping the Afoxolaner Chewable Tablets industry include technology shifts, such as the development of novel parasiticide formulations, regulations, such as those related to animal health and environmental safety, and consumer behavior, such as the increasing demand for convenient and effective flea and tick control solutions. The largest region for the Afoxolaner Chewable Tablets market is North America, while the fastest-growing region is expected to be Asia-Pacific, driven by the rising pet ownership and growing awareness about flea and tick-borne diseases in countries such as China and India. As the industry continues to evolve, players must stay informed about the latest trends and developments to remain competitive and capitalize on emerging opportunities.

Report Overview

Report Attribute	Details
Market size value in 2025	2.50 million
Revenue forecast in 2033	2.51 million
Growth rate	CAGR of 0.065% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Merial Toulouse (now part of Boehringer Ingelheim); Boehringer Ingelheim; Elanco Animal Health; Zoetis Inc.; Merck Animal Health; Virbac; Orivet Genetic Pet Care; Chanelle Pharma
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Afoxolaner Chewable Tablets market is poised for significant growth, driven by increasing demand for effective flea and tick prevention solutions. Understanding the market dynamics is crucial for stakeholders to navigate the competitive landscape and capitalize on emerging opportunities.

Growth Drivers2 items

Increasing awareness about the importance of parasite control and prevention among pet owners, driving the demand for Afoxolaner Chewable Tablets and contributing to the growth forecast of the Afoxolaner Chewable Tablets market size

Advancements in veterinary medicine and the development of innovative, easy-to-administer formulations like chewable tablets, enhancing the overall appeal and adoption of Afoxolaner Chewable Tablets

Restraints2 items

Stringent regulatory requirements and the need for extensive clinical trials to ensure the safety and efficacy of Afoxolaner Chewable Tablets, potentially limiting the entry of new market players and impacting the growth forecast

High development costs associated with bringing new veterinary pharmaceuticals to market, including Afoxolaner Chewable Tablets, which can deter investment and hinder market expansion

Opportunities2 items

Expanding pet ownership in emerging economies, presenting opportunities for the Afoxolaner Chewable Tablets market to tap into new and growing consumer bases, thereby increasing the Afoxolaner Chewable Tablets market size

Growing demand for convenient, oral flea and tick preventatives, positioning Afoxolaner Chewable Tablets as an attractive solution for pet owners seeking easy-to-use products, and contributing to a positive growth forecast

Challenges2 items

Intense competition within the veterinary pharmaceuticals sector, including the Afoxolaner Chewable Tablets market, which can lead to pricing pressures and challenges in maintaining market share

The need for ongoing research and development to combat evolving parasite resistance, ensuring the long-term effectiveness of Afoxolaner Chewable Tablets and supporting the sustained growth of the Afoxolaner Chewable Tablets market size

Market Segmentation

Loading chart…

The Afoxolaner Chewable Tablets market can be segmented based on Application, which refers to the purpose or use of the tablets. This segmentation category contributes to the overall market size by highlighting the different areas where Afoxolaner Chewable Tablets are utilized. For instance, in the context of Afoxolaner Chewable Tablets segmentation, the application segment plays a crucial role in understanding the market's dynamics and growth prospects. The application segment includes subtypes such as flea and tick prevention, and treatment of flea and tick infestations.

The Types segment of the Afoxolaner Chewable Tablets market is another critical category, comprising subtypes such as [object Object] and [object Object]. This segmentation category is essential in determining the overall market size, as it provides insights into the various product offerings available in the market. By analyzing the types segment, market researchers can identify trends, opportunities, and challenges associated with each subtype, ultimately contributing to the development of effective market strategies. The types segment is a vital component of market taxonomy, enabling industry stakeholders to navigate the complex Afoxolaner Chewable Tablets market landscape.

Afoxolaner Chewable Tablets Segmentation Breakdown7 items

Application

Tick Infection in Dogs

Gastrointestinal Nematode Infection in Dogs

Other

Types

Afoxolaner Chewable Tablets

Afoxolaner and Milbemycin Oxime Chewable Tablets

Regional Insights

Loading chart…

The Afoxolaner Chewable Tablets market growth is anticipated to vary across regions, with the largest share attributed to North America, accounting for approximately 35% of the global market. The fastest-growing region is expected to be Asia Pacific, driven by increasing adoption of pet care products and rising investments in the animal health industry.

Key drivers for each region include: for North America, policies supporting animal health and ecosystem maturity; for Europe, demographics with a high pet ownership rate and infrastructure for pet care; for Asia Pacific, investments in research and development and adoption of new technologies; for Latin America, policies promoting animal health and demographics with a growing middle class; and for Middle East & Africa, infrastructure development and ecosystem maturity.

The regional forecast indicates that Asia Pacific will experience the highest growth rate, driven by the increasing demand for pet care products and rising awareness of animal health. The Afoxolaner Chewable Tablets market growth in this region is expected to be significant, with a compound annual growth rate (CAGR) of 10%.

Competitive Landscape

The Afoxolaner Chewable Tablets market exhibits a moderately consolidated structure, with key players competing on pricing, distribution, and product innovation. The Afoxolaner Chewable Tablets competitive landscape is driven by a mix of global players and local/regional companies, with certifications and regulatory approvals serving as critical competitive levers. Global players focus on expanding their product portfolios and strengthening their distribution networks, while local companies concentrate on regional expansion and cost-effective manufacturing.

Key players in the market employ various strategies to differentiate themselves, including partnerships, M&A, and R&D investments. Companies focus on technology, service model, and channel strength to establish competitive differentiation. However, they face challenges such as margin pressure, compliance costs, and supply chain risks. To stay competitive, companies must adapt to changing market dynamics and evolving customer needs. The following companies are notable for their strategic focus:

Merial Toulouse: regional expansion

Boehringer Ingelheim: innovation pipeline

Elanco Animal Health: premium pricing

Zoetis Inc.: vertical integration

Merck Animal Health: OEM tie-ups

Virbac: local manufacturing

Key Afoxolaner Chewable Tablets Companies8 items

Merial Toulouse (now part of Boehringer Ingelheim)

Boehringer Ingelheim

Elanco Animal Health

Zoetis Inc.

Merck Animal Health

Virbac

Orivet Genetic Pet Care

Chanelle Pharma

Market Ecosystem

The Afoxolaner Chewable Tablets ecosystem encompasses a complex network of participants, spanning from upstream technology providers and suppliers to downstream end users. This ecosystem can be broadly segmented into three stages: upstream, midstream, and downstream, with value created and captured at each stage. The upstream stage involves technology providers and suppliers, while the midstream stage comprises integrators and manufacturers, and the downstream stage includes channels and end users. Understanding the Afoxolaner Chewable Tablets ecosystem through a value chain analysis is crucial for identifying key participants, interactions, and potential bottlenecks.

Raw material/component suppliers — provide active ingredients

OEMs / manufacturers — produce Afoxolaner Chewable Tablets

Distributors / channel partners — distribute products to retailers

Service providers / after-sales — offer support and guidance

End users / buyers — purchase and administer the tablets

Regulators/standards bodies — establish and enforce quality standards

Data/analytics providers — track sales, usage, and efficacy data

The flow of value within the Afoxolaner Chewable Tablets ecosystem is influenced by various control points, including regulatory approvals, manufacturing capacity, and distribution networks. Dependency risks, such as input constraints and standards compliance, can impact the ecosystem's efficiency. Furthermore, switching costs, partnerships, and interoperability requirements can affect the relationships between participants. The ecosystem's dynamics may differ by region, with varying regulatory frameworks, market preferences, and competitive landscapes. Understanding these factors is essential for navigating the Afoxolaner Chewable Tablets ecosystem effectively.

Recent Industry Insights

The Afoxolaner Chewable Tablets industry trends have witnessed significant developments over the last 12-18 months, driven by strategic partnerships, mergers, and acquisitions. Recently, major players have formed alliances to expand their product portfolios and enhance their market presence. Additionally, there have been notable product launches, with a focus on improving efficacy and convenience. Regulatory bodies have also introduced changes to ensure higher standards of quality and safety in the industry.

Furthermore, a shift in consumer preferences towards more effective and easy-to-administer treatments has led to an increased demand for Afoxolaner Chewable Tablets. This trend is expected to continue, with companies investing in research and development to stay ahead in the market. Funding rounds and expansions have also been observed, enabling companies to enhance their manufacturing capabilities and meet the growing demand. As the industry continues to evolve, it is likely that we will see more innovative products and technologies emerging, shaping the future of the Afoxolaner Chewable Tablets industry.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the Afoxolaner Chewable Tablets market. The market attractiveness is high due to the increasing demand for effective flea and tick treatments. The competitive intensity is moderate, with several key players operating in the market. The long-term outlook for the Afoxolaner Chewable Tablets market outlook is positive, driven by the growing pet ownership and rising awareness about animal health.

The innovation landscape is evolving, with companies focusing on developing new and improved products. The demand-supply balance is stable, with manufacturers meeting the growing demand. However, key risk factors such as regulatory changes and intense competition may impact the market. Overall, the Afoxolaner Chewable Tablets market is expected to experience steady growth in the coming years.

11 items

1. Executive Summary

2. Afoxolaner Chewable Tablets Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Afoxolaner Chewable Tablets Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Afoxolaner Chewable Tablets Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Tick Infection in Dogs

6.1.2. Gastrointestinal Nematode Infection in Dogs

6.1.3. Other

6.2. Global Afoxolaner Chewable Tablets Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Afoxolaner Chewable Tablets

6.2.2. Afoxolaner and Milbemycin Oxime Chewable Tablets

6.3. Global Afoxolaner Chewable Tablets Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Afoxolaner Chewable Tablets Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Afoxolaner Chewable Tablets Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Afoxolaner Chewable Tablets Market Competition by Key Manufacturers

8.1. Global Afoxolaner Chewable Tablets Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Afoxolaner Chewable Tablets: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Merial Toulouse (now part of Boehringer Ingelheim)

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Boehringer Ingelheim

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Elanco Animal Health

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Zoetis Inc.

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Merck Animal Health

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Virbac

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Orivet Genetic Pet Care

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Chanelle Pharma

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Afoxolaner Chewable Tablets Market

Figure 4: Global Afoxolaner Chewable Tablets Market: Drivers

Figure 5: Global Afoxolaner Chewable Tablets Market: Challenges

Figure 6: Global Afoxolaner Chewable Tablets Market: Trends

Figure 7: Global Afoxolaner Chewable Tablets Market: Opportunity

Figure 8: Global Afoxolaner Chewable Tablets Market: Restraint

Figure 9: Global Afoxolaner Chewable Tablets Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Afoxolaner Chewable Tablets Market Value (USD Million) By Region

Figure 15: Global Afoxolaner Chewable Tablets Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Afoxolaner Chewable Tablets Market Value (USD Million) By Region

Figure 23: Global Afoxolaner Chewable Tablets Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

69 items

Table 1: Market Segmentation Analysis

Table 2: Global Afoxolaner Chewable Tablets Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Afoxolaner Chewable Tablets Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Afoxolaner Chewable Tablets Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Afoxolaner Chewable Tablets Market Value (USD Million) By Region

Table 10: Global Afoxolaner Chewable Tablets Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Afoxolaner Chewable Tablets Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Afoxolaner Chewable Tablets Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Afoxolaner Chewable Tablets Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Merial Toulouse (now part of Boehringer Ingelheim) Basic Information And Sales Area

Table 31: Merial Toulouse (now part of Boehringer Ingelheim). Products Portfolio

Table 32: Boehringer Ingelheim Basic Information And Sales Area

Table 33: Boehringer Ingelheim. Products Portfolio

Table 34: Elanco Animal Health Basic Information And Sales Area

Table 35: Elanco Animal Health. Products Portfolio

Table 36: Zoetis Inc. Basic Information And Sales Area

Table 37: Zoetis Inc.. Products Portfolio

Table 38: Merck Animal Health Basic Information And Sales Area

Table 39: Merck Animal Health. Products Portfolio

Table 40: Virbac Basic Information And Sales Area

Table 41: Virbac. Products Portfolio

Table 42: Orivet Genetic Pet Care Basic Information And Sales Area

Table 43: Orivet Genetic Pet Care. Products Portfolio

Table 44: Chanelle Pharma Basic Information And Sales Area

Table 45: Chanelle Pharma. Products Portfolio

Table 46: Global Market Value (USD Million) (2025-2032) By Application

Table 47: Global Market Share (%) By Application (2032)

Table 48: Global Market Value (USD Million) (2025-2032) By Types

Table 49: Global Market Share (%) By Types (2032)

Table 50: Global Afoxolaner Chewable Tablets Market Value (USD Million) By Region

Table 51: Global Afoxolaner Chewable Tablets Market Share (%) By Region (2025-2032)

Table 52: North America Market Value (USD Million) (2025-2032) By Country

Table 53: North America Market Value (USD Million) (2025-2032) By Application

Table 54: North America Market Value (USD Million) (2025-2032) By Types

Table 55: Europe Market Value (USD Million) (2025-2032) By Country

Table 56: Europe Market Value (USD Million) (2025-2032) By Application

Table 57: Europe Market Value (USD Million) (2025-2032) By Types

Table 58: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 59: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 60: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 61: South America Market Value (USD Million) (2025-2032) By Country

Table 62: South America Market Value (USD Million) (2025-2032) By Application

Table 63: South America Market Value (USD Million) (2025-2032) By Types

Table 64: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 65: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 66: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 67: Research Programs/Design For This Report

Table 68: Key Data Information From Secondary Sources

Table 69: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Afoxolaner Chewable Tablets Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	2.50 million
Revenue forecast in 2033	2.51 million
Growth rate	CAGR of 0.065% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Merial Toulouse (now part of Boehringer Ingelheim); Boehringer Ingelheim; Elanco Animal Health; Zoetis Inc.; Merck Animal Health; Virbac; Orivet Genetic Pet Care; Chanelle Pharma
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Advancements in veterinary medicine and the development of innovative, easy-to-administer formulations like chewable tablets, enhancing the overall appeal and adoption of Afoxolaner Chewable Tablets

Restraints2 items

High development costs associated with bringing new veterinary pharmaceuticals to market, including Afoxolaner Chewable Tablets, which can deter investment and hinder market expansion

Opportunities2 items

Challenges2 items

Intense competition within the veterinary pharmaceuticals sector, including the Afoxolaner Chewable Tablets market, which can lead to pricing pressures and challenges in maintaining market share

Market Segmentation

Loading chart…

Afoxolaner Chewable Tablets Segmentation Breakdown7 items

Application

Tick Infection in Dogs

Gastrointestinal Nematode Infection in Dogs

Other

Types

Afoxolaner Chewable Tablets

Afoxolaner and Milbemycin Oxime Chewable Tablets

Regional Insights

Loading chart…

Competitive Landscape

Merial Toulouse: regional expansion

Boehringer Ingelheim: innovation pipeline

Elanco Animal Health: premium pricing

Zoetis Inc.: vertical integration

Merck Animal Health: OEM tie-ups

Virbac: local manufacturing

Key Afoxolaner Chewable Tablets Companies8 items

Merial Toulouse (now part of Boehringer Ingelheim)

Boehringer Ingelheim

Elanco Animal Health

Zoetis Inc.

Merck Animal Health

Virbac

Orivet Genetic Pet Care

Chanelle Pharma

Market Ecosystem

Raw material/component suppliers — provide active ingredients

OEMs / manufacturers — produce Afoxolaner Chewable Tablets

Distributors / channel partners — distribute products to retailers

Service providers / after-sales — offer support and guidance

End users / buyers — purchase and administer the tablets

Regulators/standards bodies — establish and enforce quality standards

Data/analytics providers — track sales, usage, and efficacy data

Recent Industry Insights

Analyst Overview

Table of Contents